Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced advancements to its unified AI framework for drug target discovery, ...
PandaOmics is a cloud-based software platform that applies artificial intelligence and bioinformatics techniques to multimodal omics and biomedical text data for therapeutic target and biomarker ...
CAMBRIDGE, Mass., April 22, 2026 — Insilico Medicine (“Insilico”, 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, recently published a comprehensive ...
When Insilico Medicine’s CEO Alex Zhavoronkov, PhD, and his co-authors wrote their 2023 opinion paper on AI-powered target discovery, 1 he was thinking about how often target discovery is ...
How do you begin the discovery phase of drug development? The first stages are target identification and validation. This involves selecting a target, such as a protein, receptor, or enzyme, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results